07/23/2021 10:26 AM
Clarín.com
Society
Updated 07/23/2021 11:15 AM
The
AstraZeneca
vaccine
is "
highly effective
" with a dose to prevent serious cases of coronavirus and hospitalizations caused by the
Delta and Beta variants
, the Anglo-Swedish pharmaceutical company reported on Friday.
A study carried out in Canada with 69,533 infected with Covid-19, developed between December 2020 and May 2021, indicated that the vaccine is
82% effective with a single dose
, in the face of "hospitalization or death" caused by the
Beta variant
, first identified in South Africa.
Meanwhile, the clinical trial demonstrated an
efficacy of 87%
with a single inoculation against "hospitalization or death" caused by the
Delta variant
, and
90% against the Alpha strain
of the coronavirus,
Of the total number of
people who participated in the study
carried out by the Canadian Immunization Research Network (CIRN), 40,828
(9.7%) were positive
for any
of the variants considered "worrisome"
, while 28,705 (
6.8% ) were infected with other strains
of the coronavirus.
The analysis notes that there was not enough time to report on the effectiveness of the AstraZeneca vaccine after the second dose, although "other studies have shown an increase in efficacy."
"The efficacy of Vaxzevria (brand name) after one dose against hospitalization or death was similar to that of other vaccines tested in the study," AstraZeneca said in a statement.
The executive vice president of R&D of the Anglo-Swedish company, Mene Pangalos, stressed that the vaccine offers "a
high level of protection
"
against the "most serious forms"
of the coronavirus, even after "a single dose".
"It is essential that we continue to protect as many people as possible in all corners of the world in order to anticipate this deadly virus."
Antibody treatment
AstraZeneca admitted days ago that an antibody treatment it developed does not prevent the coronavirus, since its efficacy in people exposed to the virus has not been proven.
Antibody treatment, called AZD7442, aims to prevent and treat the disease.
However, it did not work.
"
The trial did not achieve the primary goal of preventing symptomatic cases
of Covid-19 after exposure to the virus," the company explained in an official statement.
The experiment was in phase 3 of development, that is, in large-scale clinical trials to measure its safety and efficacy.
The 1,121 people who participated in the process were adults over 18 years of age who were not vaccinated and who had been exposed to an infected person during the previous eight days.
With information from EFE and AFP
AFG
Look also
Russia assures that it will comply with the delivery of vaccines to Argentina, but that the priority is to supply its country
Johnson & Johnson Vaccine May Cause Neurodegenerative Disorders
